Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 25 | 2017 | 91 | 5.740 |
Why?
|
| Immunologic Memory | 16 | 2017 | 31 | 3.190 |
Why?
|
| Lymphocytic choriomeningitis virus | 17 | 2017 | 22 | 3.080 |
Why?
|
| Lymphocytic Choriomeningitis | 15 | 2016 | 19 | 1.660 |
Why?
|
| Lymphocyte Activation | 13 | 2015 | 80 | 1.540 |
Why?
|
| Reactive Oxygen Species | 7 | 2012 | 159 | 1.470 |
Why?
|
| Rhadinovirus | 3 | 2017 | 4 | 1.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2015 | 47 | 1.210 |
Why?
|
| Mice | 30 | 2017 | 2370 | 1.110 |
Why?
|
| Apoptosis | 9 | 2012 | 337 | 1.100 |
Why?
|
| Arenaviridae Infections | 2 | 2014 | 2 | 0.960 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2017 | 22 | 0.950 |
Why?
|
| Mice, Inbred C57BL | 20 | 2016 | 711 | 0.870 |
Why?
|
| Animals | 33 | 2017 | 7299 | 0.860 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2012 | 33 | 0.820 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2012 | 90 | 0.790 |
Why?
|
| Metalloporphyrins | 3 | 2012 | 16 | 0.790 |
Why?
|
| Cell Proliferation | 9 | 2014 | 573 | 0.730 |
Why?
|
| Membrane Proteins | 4 | 2012 | 256 | 0.730 |
Why?
|
| Cysteine | 2 | 2012 | 131 | 0.690 |
Why?
|
| Virus Latency | 2 | 2017 | 7 | 0.660 |
Why?
|
| Virus Diseases | 1 | 2017 | 19 | 0.610 |
Why?
|
| B-Lymphocytes | 3 | 2014 | 69 | 0.610 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2013 | 21 | 0.580 |
Why?
|
| Organogold Compounds | 1 | 2015 | 4 | 0.540 |
Why?
|
| Autoimmunity | 4 | 2015 | 26 | 0.530 |
Why?
|
| Antioxidants | 2 | 2012 | 114 | 0.500 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 33 | 0.470 |
Why?
|
| Cell Membrane | 1 | 2013 | 98 | 0.460 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 12 | 0.450 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 55 | 0.440 |
Why?
|
| Mice, Transgenic | 9 | 2013 | 249 | 0.430 |
Why?
|
| Peroxiredoxins | 1 | 2012 | 106 | 0.410 |
Why?
|
| Mice, Knockout | 9 | 2014 | 425 | 0.380 |
Why?
|
| Signal Transduction | 4 | 2014 | 666 | 0.370 |
Why?
|
| Free Radical Scavengers | 2 | 2012 | 11 | 0.370 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2012 | 4 | 0.330 |
Why?
|
| Gamma Rays | 2 | 2006 | 24 | 0.330 |
Why?
|
| Cell Division | 5 | 2012 | 97 | 0.330 |
Why?
|
| Cell Differentiation | 4 | 2014 | 436 | 0.320 |
Why?
|
| Dendritic Cells | 4 | 2014 | 61 | 0.290 |
Why?
|
| Electron Transport Complex I | 1 | 2006 | 3 | 0.290 |
Why?
|
| Chronic Disease | 3 | 2017 | 370 | 0.290 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2006 | 58 | 0.290 |
Why?
|
| Flow Cytometry | 5 | 2015 | 172 | 0.270 |
Why?
|
| T-Lymphocytes | 3 | 2016 | 114 | 0.270 |
Why?
|
| Cells, Cultured | 5 | 2015 | 799 | 0.270 |
Why?
|
| Mitochondria | 3 | 2016 | 174 | 0.250 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Cytokines | 4 | 2015 | 243 | 0.230 |
Why?
|
| Intracellular Membranes | 1 | 2003 | 10 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2014 | 33 | 0.230 |
Why?
|
| Organoselenium Compounds | 2 | 2016 | 3 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
| Interphase | 1 | 2002 | 1 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Down-Regulation | 4 | 2012 | 143 | 0.220 |
Why?
|
| Time Factors | 5 | 2012 | 2001 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2 | 2012 | 7 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2 | 2012 | 8 | 0.190 |
Why?
|
| Cyclohexanones | 2 | 2012 | 17 | 0.190 |
Why?
|
| Female | 10 | 2016 | 18173 | 0.190 |
Why?
|
| Actins | 2 | 2012 | 52 | 0.190 |
Why?
|
| Phosphoproteins | 2 | 2015 | 54 | 0.190 |
Why?
|
| Apolipoprotein A-I | 2 | 2010 | 68 | 0.180 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
| Photosensitizing Agents | 2 | 2016 | 19 | 0.180 |
Why?
|
| Lymphocyte Depletion | 2 | 2016 | 14 | 0.180 |
Why?
|
| Acute Disease | 4 | 2014 | 239 | 0.170 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 980 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2007 | 37 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2007 | 44 | 0.150 |
Why?
|
| Phosphorylation | 3 | 2012 | 225 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 160 | 0.140 |
Why?
|
| Photopheresis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Rhodamines | 1 | 2016 | 4 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 18 | 0.140 |
Why?
|
| Cell Survival | 2 | 2008 | 272 | 0.140 |
Why?
|
| Homeostasis | 2 | 2014 | 127 | 0.140 |
Why?
|
| DNA | 2 | 2015 | 204 | 0.140 |
Why?
|
| Interferon-gamma | 3 | 2014 | 51 | 0.140 |
Why?
|
| Mutation | 3 | 2015 | 466 | 0.140 |
Why?
|
| Acridines | 1 | 2015 | 19 | 0.130 |
Why?
|
| Platinum | 1 | 2015 | 19 | 0.130 |
Why?
|
| Urea | 1 | 2015 | 33 | 0.130 |
Why?
|
| Chilblains | 1 | 2015 | 3 | 0.130 |
Why?
|
| Viral Load | 1 | 2015 | 64 | 0.130 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2015 | 13 | 0.130 |
Why?
|
| Phenotype | 2 | 2015 | 629 | 0.130 |
Why?
|
| Exodeoxyribonucleases | 1 | 2015 | 18 | 0.130 |
Why?
|
| Interferon-beta | 2 | 2006 | 23 | 0.130 |
Why?
|
| Herpesviridae Infections | 1 | 2014 | 3 | 0.130 |
Why?
|
| Interferon Type I | 1 | 2014 | 14 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 18 | 0.130 |
Why?
|
| DNA Damage | 1 | 2015 | 88 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 20 | 0.130 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 250 | 0.130 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 10 | 0.120 |
Why?
|
| Whole-Body Irradiation | 2 | 2006 | 48 | 0.120 |
Why?
|
| Spleen | 3 | 2014 | 82 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2013 | 49 | 0.120 |
Why?
|
| Diet, Atherogenic | 2 | 2010 | 61 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 641 | 0.120 |
Why?
|
| Calcium | 1 | 2015 | 297 | 0.120 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2012 | 1 | 0.110 |
Why?
|
| Lymphopoiesis | 1 | 2012 | 4 | 0.110 |
Why?
|
| Antibody-Producing Cells | 1 | 2012 | 3 | 0.110 |
Why?
|
| Cytoprotection | 1 | 2012 | 5 | 0.110 |
Why?
|
| Cell Line | 3 | 2012 | 450 | 0.110 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2012 | 44 | 0.110 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2012 | 11 | 0.110 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 20 | 0.110 |
Why?
|
| Cricetinae | 2 | 2012 | 58 | 0.110 |
Why?
|
| Biological Transport | 1 | 2012 | 62 | 0.110 |
Why?
|
| Vaccinia virus | 1 | 2012 | 15 | 0.110 |
Why?
|
| Diacylglycerol Kinase | 1 | 2012 | 2 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 114 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2012 | 281 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2012 | 72 | 0.100 |
Why?
|
| Antigens, Viral | 1 | 2011 | 18 | 0.100 |
Why?
|
| Inflammation | 1 | 2015 | 507 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2014 | 200 | 0.100 |
Why?
|
| Adoptive Transfer | 3 | 2012 | 16 | 0.100 |
Why?
|
| Antigens | 2 | 2007 | 31 | 0.100 |
Why?
|
| Listeria monocytogenes | 1 | 2010 | 8 | 0.090 |
Why?
|
| Humans | 8 | 2016 | 29123 | 0.090 |
Why?
|
| Interleukin-12 | 1 | 2010 | 26 | 0.090 |
Why?
|
| Interleukin-23 | 1 | 2010 | 14 | 0.090 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2009 | 75 | 0.080 |
Why?
|
| Azoles | 1 | 2008 | 2 | 0.080 |
Why?
|
| Sulfhydryl Reagents | 1 | 2008 | 5 | 0.080 |
Why?
|
| Ethylmaleimide | 1 | 2008 | 6 | 0.080 |
Why?
|
| Virulence | 1 | 2008 | 19 | 0.080 |
Why?
|
| Macrophages, Peritoneal | 1 | 2008 | 19 | 0.080 |
Why?
|
| Aortic Diseases | 1 | 2009 | 54 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2009 | 105 | 0.080 |
Why?
|
| Lymphatic Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 51 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2007 | 15 | 0.080 |
Why?
|
| Sulfinic Acids | 1 | 2007 | 11 | 0.080 |
Why?
|
| Cholesterol | 1 | 2009 | 229 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 441 | 0.080 |
Why?
|
| Lymph Nodes | 3 | 2014 | 92 | 0.070 |
Why?
|
| Rotenone | 1 | 2006 | 2 | 0.070 |
Why?
|
| Ionomycin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 12 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 5 | 0.070 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 7 | 0.070 |
Why?
|
| Lymphocyte Count | 3 | 2014 | 23 | 0.070 |
Why?
|
| Membrane Potentials | 2 | 2003 | 80 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 7 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 37 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 22 | 0.070 |
Why?
|
| Cell Count | 1 | 2006 | 50 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2006 | 100 | 0.070 |
Why?
|
| Peptides | 1 | 2006 | 118 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 486 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 9 | 0.060 |
Why?
|
| Viral Structural Proteins | 1 | 2003 | 7 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 142 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2003 | 42 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 859 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2004 | 172 | 0.060 |
Why?
|
| Caspases | 1 | 2003 | 31 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2003 | 33 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2009 | 698 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2003 | 126 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 212 | 0.060 |
Why?
|
| Immunization, Secondary | 1 | 2002 | 9 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 73 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2003 | 183 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1423 | 0.050 |
Why?
|
| Male | 5 | 2016 | 17815 | 0.050 |
Why?
|
| Receptors, LDL | 2 | 2010 | 64 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2016 | 23 | 0.040 |
Why?
|
| Verapamil | 1 | 2016 | 7 | 0.040 |
Why?
|
| Light | 1 | 2016 | 25 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 113 | 0.040 |
Why?
|
| Macrophages | 2 | 2010 | 188 | 0.040 |
Why?
|
| Lymphoma | 1 | 2016 | 36 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2016 | 139 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 46 | 0.030 |
Why?
|
| Antibodies | 1 | 2015 | 53 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 46 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 240 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 7 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 350 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 251 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 26 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 30 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 681 | 0.030 |
Why?
|
| Adult | 1 | 2016 | 8426 | 0.030 |
Why?
|
| RNA Caps | 1 | 2012 | 1 | 0.030 |
Why?
|
| Natural Killer T-Cells | 1 | 2012 | 2 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2012 | 3 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2012 | 3 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2012 | 25 | 0.030 |
Why?
|
| Purines | 1 | 2012 | 16 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2012 | 14 | 0.030 |
Why?
|
| Aged | 1 | 2016 | 9492 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 57 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2012 | 6 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2012 | 12 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2012 | 103 | 0.030 |
Why?
|
| Clone Cells | 1 | 2012 | 36 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2012 | 21 | 0.030 |
Why?
|
| Middle Aged | 1 | 2016 | 10834 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2012 | 44 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 152 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2012 | 69 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2012 | 100 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 33 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 81 | 0.020 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 6 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 20 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 165 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 422 | 0.020 |
Why?
|
| Maleimides | 1 | 2009 | 4 | 0.020 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2009 | 2 | 0.020 |
Why?
|
| Lipids | 1 | 2010 | 209 | 0.020 |
Why?
|
| Losartan | 1 | 2009 | 69 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2009 | 37 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2009 | 116 | 0.020 |
Why?
|
| Indoles | 1 | 2009 | 58 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 68 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 42 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2009 | 77 | 0.020 |
Why?
|
| Aorta | 1 | 2009 | 103 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 203 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 5 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 52 | 0.020 |
Why?
|
| TYK2 Kinase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2006 | 8 | 0.020 |
Why?
|
| Interleukin-7 | 1 | 2006 | 11 | 0.020 |
Why?
|
| Tyrosine | 1 | 2006 | 22 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2006 | 50 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2006 | 30 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 1604 | 0.020 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2004 | 4 | 0.020 |
Why?
|
| Pregnancy | 1 | 2007 | 815 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2003 | 5 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 42 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2003 | 69 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2003 | 68 | 0.010 |
Why?
|